Alpha-1 Antitrypsin Deficiency Research Report 2025-2035: Market Enters Growth Phase as Established Augmentation Therapies Converge with Advancing Gene and RNA Pipelines [Yahoo! Finance]
Arrowhead Pharmaceuticals, Inc. (ARWR)
Last arrowhead pharmaceuticals, inc. earnings: 2/5 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.arrowheadpharma.com/investor-relations
Company Research
Source: Yahoo! Finance
The AATD market is in its growth stage, fueled by increased R&D in protein augmentation, gene therapies, and rising awareness. Established treatments include intravenous augmentation therapy, with inhaled formulations and emerging gene-editing therapies in development. North America leads the market thanks to strong infrastructure and support, with Europe and Asia-Pacific rapidly following. Despite high costs, the therapeutic landscape presents expansive opportunities for innovation and market expansion through 2035. Key players include Arrowhead Pharmaceuticals and Sanofi S.A. Dublin, Feb. 27, 2026 (GLOBE NEWSWIRE) -- The "Alpha-1 Antitrypsin Deficiency Market - A Global and Regional Analysis: Focus on Indication, Route of Administration, Country, 2025-2035" report has been added to ResearchAndMarkets.com's offering. This report provides a comprehensive competitive analysis of pharmaceutical companies developing and commercializing treatment solutions for Alpha-1 Antitrypsin Defi
Show less
Read more
Impact Snapshot
Event Time:
ARWR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARWR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARWR alerts
High impacting Arrowhead Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ARWR
News
- Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events [Yahoo! Finance]Yahoo! Finance
- Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 EventsBusiness Wire
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $100.00 price target on the stock.MarketBeat
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) was upgraded by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a> from a "sell (d-)" rating to a "hold (c-)" rating.MarketBeat
- Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After A Strong 1 Year Shareholder Return [Yahoo! Finance]Yahoo! Finance
ARWR
Earnings
- 2/5/26 - Miss
ARWR
Sec Filings
- 2/5/26 - Form 10-Q
- 2/5/26 - Form 8-K
- 1/27/26 - Form ARS
- ARWR's page on the SEC website